Conference Offers Continuing Education for Health Care Professionals
The American Brain Tumor Association, in joint sponsorship with Cleveland Clinic, will present the 15th Annual Brain Tumor Update and 4th Annual International Symposium on Long-term Control of Metastases to the Brain and Spine on Saturday, Nov. 9 and Sunday, Nov. 10 at the Bellagio Hotel in Las Vegas. The results of a recent ABTA survey of health care professionals across the United States informed the development of a special “Partners in Care” conference track, aimed specifically at nurses, social workers and physicians seeking to advance their knowledge of issues that directly impact brain tumor patients and their families. This activity has been approved for AMA PRA Category 1 Credits™ and is pending approval from the National Association of Social Workers. Continuing Education Units are available for nurses. Click here to learn more and register.
October Webinar Focuses on Complementary TherapiesToday, more hospitals and medical centers are offering—and new research is supporting—the use of complementary therapies to help minimize brain tumor and treatment side effects. Many complementary therapies, used as part of an overall treatment plan, and with the consent of your medical team, have the potential to improve overall health and life quality in brain tumor patients. This free webinar, presented by Mary Hardy, MD, medical director for Simms/Mann-UCLA Center for Integrative Medicine at the University of California Los Angeles’ Jonsson Comprehensive Cancer Center, will discuss the use of complementary therapies and nutrition while navigating a brain tumor diagnosis. Click here to register.
Holiday CardsSend the holiday card that gives back. Purchase your holiday cards from the ABTA and we'll receive 50% of the profits from the sale, along with 100% of any additional donation you make. Prices start at $29 for a box of 25, cards can be personalized with your name or special message. View and order online by clicking here or call 888-487-5567.
Walk. Run. Breakthrough.
The autumn is a busy time for the ABTA’s two signature fundraising programs. Team Breakthrough, the ABTA’s endurance team, will have 75 runners participating in the Bank of America Chicago Marathon on Oct. 13. They’ve raised more than $110,000 to date and are still going strong! To learn more about Team Breakthrough, visit www.abtateambreakthrough.org.
|ABTA staff celebrating Team Breakthrough's
fundraising accomplishment with
100Grand candy bars!
The Breakthrough for Brain Tumors 5K Run & Walk program will host the inaugural Dallas BT5K on Oct. 26, and then head to New York City for the 2nd annual BT5K on Nov. 9. For more information on either event, visit www.bt5k.org.
ABTA Accepting Discovery Grant Letters of Intent
The ABTA began accepting Letters of Intent (LOI) for the 2014-2015 Discovery Grant program. Discovery grants are one-year, $50,000 awards that fund high-impact projects with the potential to change current diagnostics or treatments for adult and/or pediatric brain tumor care. This year, priority will be given to concepts focused on experimental therapeutics and experimental therapeutics with reduced toxicities.
The deadline for LOI’s is noon CST on October 9, 2013. After LOI’s are submitted, selected researchers will be invited to submit a full proposal for funding consideration. For more details about our Discovery Grant program and process, visit http://www.abta.org/advancing-research/research-grants/.
A Marker to Predict Glioblastoma Recurrence Researchers at Japan’s Tohoku University School of Medicine recently studied the potential for the protein CD133 to predict glioblastoma recurrence. The researchers examined tissue from 99 patients with GBM who experienced recurrence, measured CD133 levels in these tissues, then correlated the timing and location of the regrowth with the patients’ clinical and genetic factors. The results, published in the journal, Neuro-oncology (September 2013), suggest that levels of CD133 were higher in tumors that recurred further from the primary site than tumors that recurred closer to the primary site. Higher levels of CD133 were also associated with earlier tumor recurrence. Read the abstract here.
Motor Function After Stereotactic Radiosurgery for Brain MetastasesStereotactic radiosurgery (SRS) is a primary treatment option for many patients with brain metastases. Researchers from the University of Pittsburgh Medical Center and New York University Langone Medical Center studied outcomes of patients whose tumors were located in the motor cortex – the area of the brain which controls voluntary movements. Medical records from 94 patients with brain metastases in the motor cortex who underwent SRS between 2002 and 2012 were studied. Researchers found that motor function in 31% of these patients improved after SRS, and remained stable in 50%. Click here to read more.
Reduced CT Scan Radiation Levels With the use of CT scans on the rise, and the primary use being in the diagnosis of pediatric disorders, researchers at Seattle Children's Hospital studied the potential benefits and risks of using low-dose (reduced dose) radiation in CT head scans. Scientists looked at records from all of their patients who received low-dose head CT scans between October 2011 and November 2012. Researchers found that the scans provided adequate diagnostic imaging, and patients did not require follow-up full-dose CT scans as a result of poor image quality on low-dose CT scan. Details of the study appeared in the Journal of Neurosurgery: Pediatrics (October 2013). Click here for more information.
Founded in 1973, the American Brain Tumor Association was the first and is now the only national organization committed to funding brain tumor research and providing information, support and educational resources for all age groups and all tumor types. For more information, visit www.abta.org or call 800-886-ABTA (2282).
This information is provided by the American Brain Tumor Association, 8550 W. Bryn Mawr Ave., Suite 550, Chicago, IL 60631. For more information about the American Brain Tumor Association, call toll-free 866-659-1030, write firstname.lastname@example.org or visit www.abta.org.
The "American Brain Tumor Association" name and logo, the "Breakthrough for Brain Tumors" name and logo, the "Team Breakthrough" name and logo and "TrialConnect" are registered trademarks of the American Brain Tumor Association. All rights reserved.
Having Fun Raising Funds
To learn more about our events, to search for events in your state, or to learn how to host your own volunteer fundraising event, visit:
Team Breakthrough Bank of America Chicago Marathon
October 13, 2013
Corks for a Cure
October 18, 2013
Park Ridge, IL
Breakthrough for Brain Tumors Dallas 5K Run & Walk
October 26, 2013
Breakthrough for Brain Tumors NYC 5K Run & Walk
November 9, 2013
New York, NY
Connect with Others at Connections Online
The ABTA's Connections online support community links patients, families, friends, caregivers and health care professionals with each other for support and inspiration. It is a safe place to visit, join and interact with members of the brain tumor community nationally and around the world.
Get Caregiver Support through MyCaringLink
MyCaringLink, powered by Lotsa Helping Hands, is the ABTA's personalized online caregiver support tool.
Find a Clinical Trial Through TrialConnect
The ABTA's TrialConnect, a free and confidential service administered by EmergingMed, is offered in English and Spanish. Read more
Our Care Consultants provide brain tumor information, support and education for patients, families and health care professionals. Write email@example.com
or call our toll-free CareLine at 800-886-ABTA (2282).